Liraglutide

At a glance

---

What is liraglutide?

Liraglutide is a synthetic peptide drug that mimics GLP-1 (glucagon-like peptide-1), a hormone your gut naturally releases after eating. It's a 31-amino-acid chain with 97% structural homology to native human GLP-1 — more similar to the natural hormone than any other approved GLP-1 drug.^[5]

Developed by Novo Nordisk in Denmark, liraglutide was the molecule that proved the GLP-1 class could work as a practical medicine. Native GLP-1 is destroyed within about 2 minutes by an enzyme called DPP-4, making it useless as a drug. Novo Nordisk's solution was two modifications:

• Arg at position 34: Prevents fatty acid binding at an unintended site
• C-16 fatty acid (palmitic acid) at Lys26: Enables albumin binding in the blood, which acts as a slow-release reservoir and extends the half-life to approximately 13 hours

This 13-hour half-life made once-daily dosing possible — a significant advance over the first GLP-1 drugs (like exenatide), which required twice-daily injections. But it was still far shorter than the 7-day half-life that Novo Nordisk would later achieve with semaglutide by switching to a C-18 fatty diacid.

Liraglutide is sold under two brand names: Victoza (for type 2 diabetes, approved 2010) and Saxenda (for chronic weight management, approved 2014). Saxenda became the first GLP-1 receptor agonist approved for adolescents aged 12 and older with obesity in December 2020.^[8] Wegovy (semaglutide) later received a comparable adolescent obesity expansion in 2022, so Saxenda is no longer the only GLP-1 option with an ages-12+ obesity indication.^[10]

The pioneer story matters. Liraglutide was the drug that generated the first cardiovascular outcomes data for the GLP-1 class (LEADER, 2016). It was the evidence from LEADER that convinced the medical community — and the FDA — that GLP-1 agonists weren't just glucose-lowering drugs, but cardiovascular medicines. Without liraglutide, semaglutide's path to approval would have looked very different.

---

How it works

In plain terms, liraglutide tells your body three things: release more insulin (but only when blood sugar is already high), slow down digestion so you feel full longer, and reduce appetite signals in the brain. The mechanism is identical to semaglutide — the difference is how long the drug stays active in the body.

Detailed mechanism (for advanced readers)

Liraglutide is a selective GLP-1 receptor agonist. Its mechanisms of action include:

• Glucose-dependent insulin secretion: Activates GLP-1 receptors on pancreatic beta cells, potentiating insulin release only when glucose is elevated. This glucose-dependent mechanism means liraglutide alone rarely causes hypoglycemia — a key safety advantage over sulfonylureas and insulin.
• Glucagon suppression: Inhibits glucagon release from pancreatic alpha cells, reducing hepatic glucose production. This effect is also glucose-dependent.
• Gastric emptying delay: Slows gastric motility, contributing to both post-prandial glucose reduction and increased satiety. This is also the primary driver of GI side effects (nausea, vomiting). Notably, the gastric emptying effect of liraglutide shows tachyphylaxis (diminishes over time), while the weight loss effect persists.^[5]
• Central appetite regulation: Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety. This central effect is the primary driver of weight loss at the 3.0 mg dose (Saxenda).
• Cardiovascular effects: Anti-inflammatory effects on vasculature, reduced atherogenesis, improvements in lipid profiles and blood pressure. The LEADER trial demonstrated these are clinically meaningful.

How it differs from related compounds:

• vs. Semaglutide (Ozempic/Wegovy): Liraglutide uses a C-16 palmitic acid for albumin binding; semaglutide uses a C-18 fatty diacid. This single chemical difference explains the half-life gap: ~13 hours (daily dosing) vs. ~7 days (weekly dosing). Semaglutide also has an Aib8 substitution that provides additional DPP-4 resistance. Net result: semaglutide produces roughly twice the weight loss (~15% vs. ~8%).
• vs. Tirzepatide (Mounjaro/Zepbound): Liraglutide is a pure GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist. Tirzepatide achieves even greater weight loss (~20%) through dual receptor activation.
• vs. Exenatide (Byetta): Liraglutide has greater structural homology to native GLP-1 (97% vs. ~53%) and a longer half-life. This translates to superior glycemic control and weight loss in head-to-head trials.

---

What the research says

Liraglutide was the GLP-1 receptor agonist that proved the class could reduce cardiovascular events — not just blood sugar. The LEADER trial's 9,340 patients made it possible for semaglutide, tirzepatide, and the entire incretin class to be taken seriously as cardiovascular medicines.

Research timeline

Liraglutide's research spans nearly two decades, from early dose-finding studies through the landmark LEADER cardiovascular outcomes trial:

Key clinical trials

Liraglutide's clinical evidence base includes the SCALE program for weight management, the LEAD program for diabetes, and the landmark LEADER cardiovascular outcomes trial:

---

What the evidence shows

Like semaglutide, the claims about liraglutide are largely supported by strong clinical evidence. Here's the evidence behind the most common questions:

---

Safety & side effects

Liraglutide has one of the longest safety track records in the GLP-1 class — over 15 years of post-marketing surveillance from millions of prescriptions worldwide. The side effect profile is well-characterized and similar to other GLP-1 receptor agonists.^[9]

Common side effects (from clinical trials)

Gastrointestinal effects are the most common and are dose-dependent. They typically peak during dose escalation and improve over 4-8 weeks:

• Nausea: ~40% (vs. ~14% placebo) — the most common side effect
• Diarrhea: ~21%
• Constipation: ~19%
• Vomiting: ~16%
• Headache: ~14%
• Dyspepsia: ~9%
• Fatigue: ~8%
• Injection site reactions: ~13% (mild)

Serious safety concerns

• Pancreatitis: Rare but documented. Cases of acute pancreatitis have been reported. Liraglutide should be discontinued if pancreatitis is suspected.

• Gallbladder disease: Increased risk of cholelithiasis (gallstones), particularly with higher doses used for weight management.

• Acute kidney injury: Reported, likely secondary to dehydration from severe GI side effects. Adequate hydration is essential.

• Hypoglycemia: Low risk when used alone; increased risk when combined with insulin or sulfonylureas.

• Heart rate increase: Mean increase of 2-3 bpm observed in clinical trials. Clinical significance is uncertain.

• Surgery and anesthesia (delayed gastric emptying): Under the FDA's 2024 class-wide GLP-1 label update, liraglutide's label carries a Warnings & Precautions note on the risk of pulmonary aspiration during general anesthesia or deep sedation. Because the drug slows gastric emptying, there are rare postmarketing reports of retained gastric contents despite recommended fasting. Tell your care team you take liraglutide before any surgery or procedure. The label also notes postmarketing gastrointestinal reactions including ileus and intestinal obstruction. Specific perioperative "hold" guidance (when to pause the drug before a procedure) comes from anesthesiology societies, not the FDA label.^[9]

• Muscle and micronutrient status during weight loss: As with any GLP-1 agonist, part of the weight lost is lean mass, and appetite suppression can reduce intake of protein and micronutrients. A 2026 European consensus statement (EASO, EFAD and ECPO) sets out practical nutrition, physical-function and psychological guidance for adults on incretin-based therapy.^[19]

Class-level questions: eyes, hair, and pregnancy

Three questions came into sharper focus across the GLP-1 class in mid-2026. None of the underlying studies isolates liraglutide, but liraglutide is in the class they studied, so it is worth knowing where things stand.

Eyes (NAION). A possible link between GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy — a rare optic-nerve event sometimes called an "eye stroke" — has been debated for two years, mostly on semaglutide data. In July 2026, Annals of Internal Medicine published two independent studies on the same day. A US target trial emulation in commercial claims found an 18-month risk of ischemic optic neuropathy of 8.5 versus 5.5 per 10,000 compared with SGLT2 inhibitors (risk difference 3.0 per 10,000, 95% CI 0.4–5.7) — a number needed to harm of about 3,300.^[12] A Swedish nationwide cohort covering 2013–2024 found a one-year risk of 0.04% versus 0.02% (RR 1.93, 95% CI 1.00–3.73), and when the analysis was restricted to people already taking metformin — a more comparable group — the association shrank substantially (RR 1.40, 0.64–3.05), which the authors read as evidence that some of the signal reflects who takes these drugs rather than the drugs themselves.^[13] The practical takeaway is the same one the ophthalmology societies reached: this is not a reason to stop treatment reflexively, and sudden painless vision loss in one eye warrants prompt ophthalmology evaluation regardless.

Hair. A BMJ target trial emulation published in July 2026 found that adults with type 2 diabetes starting a GLP-1 receptor agonist had more diagnosed alopecia than those starting an SGLT-2 inhibitor (HR 1.37, 95% CI 1.08–1.73) or a DPP-4 inhibitor (HR 1.68, 1.28–2.20), strongest for the non-scarring subtype. It is a single health system, the outcome is a diagnostic code, and the effect attenuates after negative-control calibration. Weight loss from any cause can trigger telogen effluvium — a temporary shedding phase — which this design cannot separate from a drug effect.^[14]

Pregnancy. Liraglutide remains contraindicated in pregnancy. But the evidence for people who conceive unexpectedly on a GLP-1 drug is now much better than a single study: a meta-analysis of 8 studies and 186,598 pregnancies found no significant difference in gestational diabetes, preterm birth, preeclampsia or hypertensive disorders,^[15] and an international multidisciplinary consensus guideline published the same summer reported that no included study found an increase in congenital anomalies, along with practical guidance on contraception, preconception planning and lactation.^[16] None of these papers declares the drug safe in pregnancy, and they draw on overlapping retrospective cohorts, so they are not independent confirmations.

What makes liraglutide's safety data notable

Contraindications and drug interactions

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Hypersensitivity to liraglutide or excipients
• Pregnancy (Category X — teratogenic in animal studies)

Drug interactions:

• Insulin / sulfonylureas: Increased hypoglycemia risk; dose reduction often needed
• Oral medications: Delayed gastric emptying may affect absorption of co-administered drugs
• Warfarin/anticoagulants: More frequent INR monitoring recommended during initiation
• Oral contraceptives: Potential reduced absorption; patients should be counseled accordingly

---

How people use it

Like semaglutide, liraglutide has FDA-approved dosing protocols validated in large clinical trials. Both formulations require gradual dose escalation to minimize GI side effects.

FDA-approved dosing — Victoza (type 2 diabetes)

FDA-approved dosing — Saxenda (weight management)

Administration

• Subcutaneous injection (both Victoza and Saxenda): Abdomen, thigh, or upper arm. Once daily, at any time of day, with or without food. Comes in a pre-filled pen — no reconstitution needed.
• Daily vs. weekly: This is the key practical difference from semaglutide. Some patients prefer the daily ritual; others find weekly dosing more convenient. Neither approach is inherently better — it's a matter of preference and clinical response.

Who might still choose liraglutide over semaglutide

• Adolescents (12-17): Saxenda was the first GLP-1 RA approved for this age group and offers daily titration flexibility, though Wegovy is also approved for adolescents 12+
• Daily dosing preference: Some patients and clinicians prefer the ability to adjust dose daily
• Cost considerations: Saxenda may be available at lower out-of-pocket cost depending on insurance
• Established safety record: 15+ years of post-marketing data vs. ~9 years for semaglutide
• Prescriber familiarity: Many endocrinologists have extensive experience with liraglutide

---

Legal & regulatory status

As of August 2026:

FDA-approved indications

Liraglutide is an FDA-approved prescription drug with multiple approved indications across two brand names:

Nothing changed for liraglutide at the FDA between late June and mid-August 2026 — no new approvals, indications, or approved label supplements.

Generics, compounding, and "follow-on" products

Liraglutide's original patents have expired, and generic versions have been approved in the US through abbreviated applications. A generic is not the same thing as a compounded or "follow-on" product: generics are held to the originator's specifications and reviewed by the FDA, while compounded preparations are not FDA-approved and follow-on products made outside that framework are not equivalent to either.

Two things are worth knowing here:

• The compounding route is narrowing. In April 2026 the FDA proposed removing liraglutide — along with semaglutide and tirzepatide — from the 503B Bulks List, which would close the last route for outsourcing facilities to compound them at scale from bulk drug substance. Secondary reporting places the close of the public comment period at July 30, 2026; we could not confirm that date, or whether a final determination has been issued, against a primary source.^[18]
• Non-originator liraglutide is not chemically interchangeable by default. A July 2026 laboratory study compared compounded and follow-on semaglutide and liraglutide against originator product and found amino acid deletions and additions, unidentified impurities, and reduced physical stability in the liraglutide follow-ons, along with a distinct set of potentially immunogenic peptides in an immune-presentation assay. This is a lab study — no patients, no clinical immunogenicity outcomes, and the authors themselves call for clinical work. We were also unable to confirm who funded it, which is worth flagging because originator manufacturers have a commercial interest in this comparison.^[17]

WADA / USADA status

Liraglutide is not prohibited under WADA anti-doping rules. It has been on WADA's Monitoring Program since 2024, alongside other GLP-1 receptor agonists. Athletes will NOT receive anti-doping violations for liraglutide use.

Insurance and access

• Most commercial insurance covers Victoza for type 2 diabetes
• Coverage for Saxenda (weight management) is expanding but inconsistent
• Without insurance: Victoza ~$900-1,100/month, Saxenda ~$1,300-1,400/month
• Manufacturer savings cards may reduce copays for eligible commercially insured patients

---

How liraglutide compares

Liraglutide vs. Semaglutide (the most important comparison)

The comparison to semaglutide is inevitable — semaglutide is literally liraglutide's successor from the same company. Here's how they differ:

The chemistry is instructive: both drugs start from the same GLP-1(7-37) backbone. Semaglutide adds an Aib8 substitution for DPP-4 resistance and uses a C-18 fatty diacid instead of liraglutide's C-16 palmitic acid. That seemingly small chemical change — two extra carbon atoms and a diacid instead of monoacid — is what enables the jump from daily to weekly dosing and from 8% to 15% weight loss.^[5]

Liraglutide in the evidence hierarchy

To understand where liraglutide sits in the broader peptide evidence landscape:

Liraglutide sits near the top of the evidence hierarchy for any peptide therapy. Its evidence base is slightly smaller than semaglutide's — but it's still orders of magnitude beyond most peptides discussed online. When someone offers you a "GLP-1 alternative" that is a research compound, this is the standard it should be measured against.

---

Related content

Peptide

Semaglutide Profile

Liraglutide's next-generation successor. Longer half-life, greater weight loss, and the most extensive evidence base of any GLP-1 agonist.

Guide

How to Evaluate a Peptide Clinic

A scorecard for evaluating prescribers and clinics offering GLP-1 receptor agonists like liraglutide.

Tool

Price Comparison Worksheet

Compare clinic and compounding pharmacy pricing for GLP-1 drugs on a like-for-like basis.

Guide

What Is 'Ozempic Face'?

The science behind facial volume loss on GLP-1 drugs. Applies to liraglutide as well as semaglutide.

---

References

1. [1]

   Pi-Sunyer X, Astrup A, Fujioka K, et al.. “A randomized, controlled trial of 3.0 mg of liraglutide in weight management.” N Engl J Med. 2015. 373(1):11-22 DOI PubMedRCT

   Landmark SCALE Obesity and Prediabetes trial. Phase III, double-blind, randomized, placebo-controlled. 3,731 participants across 191 sites in 27 countries. The trial that led to Saxenda approval.

2. [2]

   Marso SP, Daniels GH, Tanaka K, et al.. “Liraglutide and cardiovascular outcomes in type 2 diabetes.” N Engl J Med. 2016. 375(4):311-322 DOI PubMedRCT

   LEADER trial. 9,340 patients with T2D at high CV risk. Median follow-up 3.8 years. First GLP-1 receptor agonist to demonstrate cardiovascular benefit in a dedicated outcomes trial.

3. [3]

   Wadden TA, Hollander P, Klein S, et al.. “Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.” Int J Obes (Lond). 2013. 37(11):1443-1451 DOI PubMedRCT

   SCALE Maintenance trial. 422 participants. Demonstrated liraglutide's ability to maintain and extend diet-induced weight loss.

4. [4]

   Davies MJ, Bergenstal R, Bode B, et al.. “Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial.” JAMA. 2015. 314(7):687-699 DOI PubMedRCT

   SCALE Diabetes trial. 846 participants with T2D. Demonstrated significant weight loss and HbA1c improvement at 56 weeks.

5. [5]

   Knudsen LB, Lau J. “The discovery and development of liraglutide and semaglutide.” Front Endocrinol. 2019. 10:155 DOI PubMedReview

   Definitive account of liraglutide and semaglutide development from Novo Nordisk's GLP-1 analog program. Explains the chemistry behind the C-16 palmitic acid modification and why the C-18 diacid in semaglutide achieved longer half-life.

6. [6]

   Astrup A, Rossner S, Van Gaal L, et al.. “Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.” Lancet. 2009. 374(9701):1606-1616 DOI PubMedRCT

   Early Phase II dose-finding study for weight management. 564 participants. Identified the 3.0 mg dose as optimal for weight loss.

7. [7]

   le Roux CW, Astrup A, Fujioka K, et al.. “3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.” Lancet. 2017. 389(10077):1399-1409 DOI PubMedRCT

   3-year extension of the SCALE Obesity and Prediabetes trial. Showed sustained weight loss and roughly an 80% reduction in the risk of developing type 2 diabetes vs. placebo (hazard ratio 0.21, 95% CI 0.13-0.34).

8. [8]

   Kelly AS, Auerbach P, Barrientos-Perez M, et al.. “A randomized, controlled trial of liraglutide for adolescents with obesity.” N Engl J Med. 2020. 382(22):2117-2128 DOI PubMedRCT

   251 adolescents (12-17 years). Showed significant BMI reduction vs. placebo. Led to Saxenda pediatric approval (December 2020).

9. [9]

   Novo Nordisk. “Saxenda (liraglutide) injection 3 mg — full prescribing information.” 2024. Link

   FDA-approved prescribing information for chronic weight management. Includes black box warning for thyroid C-cell tumors observed in rodents.

10. [10]

    U.S. Food and Drug Administration. “New Drug Therapy Approvals 2022.” 2022. Link

    FDA CDER summary documenting Wegovy's 2022 population expansion to patients aged 12 years and older.

11. [11]

    Novo Nordisk. “Victoza (liraglutide) injection — full prescribing information.” 2024. Link

    FDA-approved prescribing information for type 2 diabetes. Includes dosing, safety data, and black box warning.

12. [12]

    Reynolds KR, O'Malley KM, Roy JA, Dave CV. “Glucagon-like peptide-1 receptor agonists and risk for ischemic optic neuropathy: a target trial emulation.” Ann Intern Med. 2026. DOI PubMedObservational study

    July 2026 target trial emulation in US commercial claims (2017–2022), adults 18–65 with type 2 diabetes. 18-month ischemic optic neuropathy risk 8.5 vs. 5.5 per 10,000 versus SGLT2 inhibitors (risk difference 3.0, 95% CI 0.4–5.7) and 7.8 vs. 4.2 per 10,000 versus DPP4 inhibitors (3.6, 1.1–6.1) — numbers needed to harm of 3,333 and 2,778. Class-level, not liraglutide-specific; NAION-specific diagnostic codes were not available.

13. [13]

    Ueda P, Svanström H, Söderling J, et al.. “Glucagon-like peptide-1 receptor agonists and risk for anterior ischemic optic neuropathy: a nationwide cohort study.” Ann Intern Med. 2026. DOI PubMedObservational study

    July 2026 Swedish nationwide cohort, 2013–2024. 62 of 107,518 GLP-1 receptor agonist initiators vs. 64 of 185,898 SGLT-2 inhibitor initiators developed anterior ischemic optic neuropathy; one-year risk 0.04% vs. 0.02% (RR 1.93, 95% CI 1.00–3.73), five-year 0.12% vs. 0.07% (1.69, 0.95–3.01). Restricting to people already on metformin attenuated the association substantially, which the authors read as evidence of residual confounding.

14. [14]

    Tang H, Zhang B, Lu Y, et al.. “Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation.” BMJ. 2026. 394:e100077 DOI PubMedObservational study

    Alopecia HR 1.37 (95% CI 1.08–1.73) vs. SGLT-2 inhibitors and 1.68 (1.28–2.20) vs. DPP-4 inhibitors, in one US health system's electronic health records. Class-level, diagnostic-code outcome, attenuates after negative-control calibration — an association, not established causation.

15. [15]

    Hattler E, Schluter H, Greene C, et al.. “Glucagon-like peptide-1 receptor agonists and risk of adverse maternal pregnancy outcomes: a systematic review and meta-analysis.” Obstet Gynecol. 2026. DOI PubMedSystematic review

    8 studies, 186,598 pregnancies (47,159 exposed). No significant differences in gestational diabetes, preterm birth, preeclampsia or hypertensive disorders of pregnancy. Built on retrospective cohorts that overlap with other syntheses.

16. [16]

    Maslin K, Shawe J, Blowers S, et al.. “Incretin-based medications in women and reproduction: a systematic scoping review and consensus guidelines for clinical practice.” Obes Rev. 2026.:e70203 DOI PubMedReview

    International multidisciplinary consensus guidance synthesising 34 articles; reports that no included study found an increase in congenital anomalies, and covers contraception, preconception planning, nutrition, pregnancy monitoring and lactation.

17. [17]

    Kopp KL, Lamberth K, Schelde O, et al.. “Impurities and potential immunogenicity associated with follow-on and compounded glucagon-like peptide-1 receptor agonists.” Pharm Res. 2026. DOI PubMedIn vitro

    Laboratory characterisation of compounded and follow-on semaglutide and liraglutide versus originator product. Found amino acid deletions and additions, unidentified impurities, and reduced physical stability for liraglutide follow-ons; an MHC-II-associated peptide proteomics assay presented potentially immunogenic peptides. In vitro only, with no patients and no clinical immunogenicity outcomes; the authors call for clinical studies. We were not able to confirm the study's funding source, which is worth knowing because originator manufacturers have a commercial interest in this comparison.

18. [18]

    U.S. Food and Drug Administration. “List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act.” 2026. LinkSafety study

    Federal Register notice (published May 1, 2026, document 2026-08552) of FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, on the reasoning that there is no 'clinical need' for outsourcing facilities to compound them from bulk drug substance. Secondary reporting places the close of the comment period at July 30, 2026; we could not confirm that date or the status of a final decision against a primary source.

19. [19]

    Dobbie LJ, Tolvanen L, Alves D, et al.. “Nutritional, functional, and psychological considerations for incretin-based therapies in adults — an EASO, EFAD, and ECPO consensus statement.” Lancet Diabetes Endocrinol. 2026. 14(9):754–777 DOI PubMedReview

    Consensus statement from the European Association for the Study of Obesity, the European Federation of the Associations of Dietitians and the European Coalition for People living with Obesity on nutrition, physical function and psychological care during incretin-based therapy.

---